02 April 2018
: Case report
Managing the Unmanageable: A Two-Staged Palliative Resection to Control Life-Threatening Duodenal Bleeding Due to Recurrent Paraganglioma
Unusual clinical course, Management of emergency care, Clinical situation which can not be reproduced for ethical reasons
Levi Y. Smucker12AEF, Ashley N. Hardy23A, Peter J. O'Neil3A, Roderich E. Schwarz123ABE*DOI: 10.12659/AJCR.907760
Am J Case Rep 2018; 19:386-391
Abstract
BACKGROUND: This report presents therapeutic decision-making and management of refractory, life-threatening duodenal bleeding in a young man with recurrent metastatic retroperitoneal paraganglioma.
CASE REPORT: The patient had been symptom free for 8 years after radioactive MIBG (metaiodobenzylguanidine) therapy. Failure of endoscopic or angiographic bleeding control led to urgent need to evaluate possible endocrine functional status, tumor curability, safety of incomplete resection, intra- and postoperative support needs, and anticipated recovery potential and postoperative function. Aside from these considerations, impact of tumor biology, alternative therapeutic options, current management guidelines, and ethical challenges of resource utilization for such complex palliative operative intervention were reviewed.
CONCLUSIONS: Based on the observed outcomes after an urgent presentation of an unusual tumor-related complication, palliation-intent therapy was justifiable even if significant treatment-related risks were expected and complex resources were required.
Keywords: Emergency Treatment, Endocrine Surgical Procedures, Gastrointestinal Hemorrhage, Palliative Care, Paraganglioma, Extra-Adrenal
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945747
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945539
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945795
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946588
Most Viewed Current Articles
21 Jun 2024 : Case report
88,518
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,005
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,154
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,640
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030